MMP-1 is a prognostic marker for hematogenous metastasis of colorectal cancer

Oncologist

Volumn 5, Issue 2, 2000, Pages 108-114

  Sunami, Eiji ^a   Tsuno, Nelson ^a   Osada, Takuya ^a   Saito, Shinsuke ^a   Kitayama, Joji ^a   Tomozawa, Shigeru ^a   Tsuruo, Takashi ^b   Shibata, Yoichi ^a   Muto, Tetsuichiro ^c   Nagawa, Hirokazu ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c CANCER INSTITUTE HOSPITAL   (Japan)

Author keywords

Colon cancer; Hematogenous metastasis; Immunohistochemistry; MMP 1

Indexed keywords

BIOCHEMICAL MARKER; COLLAGENASE; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; BASEMENT MEMBRANE; CANCER INVASION; COLON MUCOSA; COLORECTAL CANCER; ENZYME DEGRADATION; EXTRACELLULAR MATRIX; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; STROMA CELL;

EID: 17944395146     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.5-2-108     Document Type: Article

References (50)

1. Yamada T, Alpers DH, Owyang C et al. Textbook of Gastroenterology (volume two). Philadelphia, PA: J.B. Lippincott Company, Ltd., 1995:1967-2027.
2. Phillips SF, Pemberton JH, Shorter RG. The Large Intestine: Physiology, Pathophysiology, and Disease. New York, NY: Raven Press, Ltd., 1991:521-547.
3. Sugihara K, Hojo K, Moriya Y et al. Pattern of recurrence after hepatic resection for colorectal metastases. Br J Surg 1993;80:1032-1035.
4. Greenway B. Hepatic metastases from colorectal cancer: resection or not. Br J Surg 1988;75:513-519.
5. Aznavoorian S, Murphy AN, Stetler SW et al. Molecular aspects of tumor cell invasion and metastasis. Cancer 1993;71:1368-1383.
6. Liotta LA, Steeg PS, Stetler SW. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991;64:327-336.
7. Kohn EC, Liotta LA. Molecular insights into cancer invasion: strategies for prevention and intervention. Cancer Res 1995;55:1856-1862.
8. Murray GI, Duncan ME, O'Neil P et al. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat Med 1996;2:461-462.
9. Murray GI, O'Neil P, McKay JA et al. Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer. J Pathol 1998;185:256-261.
10. Scheele J, Stangl R, Altendorf HA. Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg 1990;77:1241-1246.
11. Muller D, Quantin B, Gesnel MC et al. The collagenase gene family in humans consists of at least four members. Biochem J 1988;253:187-192.
12. Ambiru S, Miyazaki M, Ito H et al. A prospective study of prognostic value of type IV collagenase activity in colorectal cancer tissue. Dig Dis Sci 1997;42:1660-1665.
13. Mori M, Barnard GF, Mimori K et al. Overexpression of matrix metalloproteinase-7 mRNA in human colon carcinomas. Cancer 1995;75(suppl 6):1516-1519.
14. Pacheco MM, Mourao M, Mantovani EB et al. Expression of gelatinases A and B, stromelysin-3 and matrilysin genes in breast carcinomas: clinico-pathological correlations. Clin Exp Metastasis 1998;16:577-585.
15. Nelimarkka LO, Nikkari ST, Ravanti LS et al. Collagenase-1, stromelysin-1 and 92 kDa gelatinase are associated with tumor necrosis factor-alpha induced morphological change of human endothelial cells in vitro. Matrix Biol 1998;17:293-304.
16. Wahl LM, Corcoran ML. Regulation of monocyte/macrophage metalloproteinase production by cytokines. J Periodontol 1993;64(suppl 5):467-473.
17. Kapila S, Xie Y. Targeted induction of collagenase and stromelysin by relaxin in unprimed and beta-estradiol-primed diarthrodial joint fibrocartilaginous cells but not in synoviocytes. Lab Invest 1998;78:925-938.
18. Vaatainen U, Lohmander LS, Thonar E et al. Markers of cartilage and synovial metabolism in joint fluid and serum of patients with chondromalacia of the patella. Osteoarthr Cartil 1998;6:115-124.
19. Brenneisen P, Wenk J, Klotz LO et al. Central role of Ferrous/Ferric iron in the ultraviolet B irradiation-mediated signaling pathway leading to increased interstitial collagenase (matrix-degrading metalloprotease (MMP)-1) and stromelysin-1 (MMP-3) mRNA levels in cultured human dermal fibroblasts. J Biol Chem 1998;273:5279-5287.
20. Ito A, Nakajima S, Sasaguri Y et al. Co-culture of human breast adenocarcinoma MCF-7 cells and human dermal fibroblasts enhances the production of matrix metalloproteinases 1, 2 and 3 in fibroblasts. Br J Cancer 1995;71:1039-1045.
21. Saarialho-Kere UK, Welgus HG, Parks WC. Divergent mechanisms regulate interstitial collagenase and 92 kDa gelatinase expression in human monocytic-like cells exposed to bacterial endotoxin. J Biol Chem 1993;268:17354-17361.
22. Pierce RA, Sandefur S, Doyle GA et al. Monocytic cell type-specific transcriptional induction of collagenase. J Clin Invest 1996;97:1890-1899.
23. Pilcher BK, Sudbeck BD, Dumin JA et al. Collagenase-1 and collagen in epidermal repair. Arch Dermatol Res 1998;290 (suppl):S37-S46.
24. Di Colandrea T, Wang L, Wille J et al. Epidermal expression of collagenase delays wound-healing in transgenic mice. J Invest Dermatol 1998;111:1029-1033.
25. Fukuda Y, Ishizaki M, Kudoh S et al. Localization of matrix metalloproteinases-1, -2, and -9 and tissue inhibitor of metalloproteinase-2 in interstitial lung diseases. Lab Invest 1998;78:687-698.
26. Ishiguro N, Ito T, Ito H et al. Relationship of matrix metalloproteinases and their inhibitors to cartilage proteoglycan and collagen turnover: analyses of synovial fluid from patients with osteoarthritis. Arthritis Rheum 1999;42:129-136.
27. Galis ZS, Suckhova MW, Lark MW et al. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994;94:2493-2503.
28. Nikkari ST, O'Brien KD, Ferguson M et al. Interstitial collagenase (MMP-1) expression in human carotid atherosclerosis. Circulation 1995;92:1393-1398.
29. Tsukifuji R, Sakai Y, Hatamochi A et al. Gene expression of matrix metalloproteinase-1 (interstitial collagenase) and matrix metalloproteinase-3 (stromelysin-1) in basal cell carcinoma by in situ hybridization using chondroitin ABC lysase. Histochem J 1997;29:401-407.
30. Kameyama K. Expression of MMP-1 in the capsule of thyroid cancer - relationship with invasiveness. Pathol Res Pract 1996;192:20-26.
31. Murray GI, Duncan ME, Arbuckle E et al. Matrix metalloproteinases and their inhibitors in gastric cancer. Gut 1998;43:791-797.
32. Bolon I, Gouyer V, Devouassoux M et al. Expression of c-ets-1, collagenase 1, and urokinase-type plasminogen activator genes in lung carcinomas. Am J Pathol 1995;147:1298-1310.
33. Polette M, Clavel C, Cockett M et al. Detection and localization of mRNAs encoding matrix metalloproteinases and their tissue inhibitor in human breast pathology. Invasion Metastasis 1993;13:31-37.
34. Okazaki I, Wada N, Nakano M et al. Difference in gene expression for matrix metalloproteinase-1 between early and advanced hepatocellular carcinomas. Hepatology 1997;25:580-584.
35. Polette M, Clavel C, Muller D et al. Detection of mRNAs encoding collagenase 1 and stromelysin 2 in carcinomas of the head and neck by in situ hybridization. Invasion Metastasis 1991;11:76-83.
36. Hewitt RE, Leach IH, Powe DG et al. Distribution of collagenase and tissue inhibitor of metalloproteinases (TIMP) in colorectal tumours. Int J Cancer 1991;49:666-672.
37. Gray ST, Yun K, Motoori T et al. Interstitial collagenase gene expression in colonic neoplasia. Am J Pathol 1993;143:663-671.
38. Polette M, Gilbert N, Stas I et al. Gelatinase A expression and localization in human breast cancers. An in situ hybridization study and immunohistochernical detection using confocal microscopy. Virchows Arch 1994;424:641-645.
39. Sledge GJ, Qulali M, Goulet R et al. Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice. J Natl Cancer Inst 1995;87:1546-1550.
40. Bu W, Tang ZY, Sun FX et al. Effects of matrix metalloproteinase inhibitor BB-94 on liver cancer growth and metastasis in a patient-like orthotopic model LCI-D20. Hepatogastroenterology 1998;45:1056-1061.
41. Watson SA, Morris TM, Robinson G et al. Inhibition of organ invasion by the matrix metalloproteinase inhibitor batimastat (BB-94) in two human colon carcinoma metastasis models. Cancer Res 1995;55:3629-3633.
42. Taraboletti G, Garofalo A, Belotti D et al. Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases. J Natl Cancer Inst 1995;87:293-298.
43. Johnson MD, Kim HR, Chesler L et al. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase. J Cell Physiol 1994;160:194-202.
44. Millar AW, Brown PD, Moore J et al. Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteers. Br J Clin Pharmacol 1998;45:21-26.
45. Nelson NJ. Inhibitors of angiogenesis enter phase III testing [news]. J Natl Cancer Inst 1998;90:960-963.
46. Nemunaitis J, Poole C, Primrose J et al. Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies. Clin Cancer Res 1998;4:1101-1109.
47. Parsons SL, Watson SA, Steele RJ. Phase I/II trial of batimastat, a matrix metalloproteinase inhibitor, in patients with malignant ascites. Eur J Surg Oncol 1997;23:526-531.
48. Rasmussen HS, McCann PP. Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. Pharmacol Ther 1997;75:69-75.
49. Wojtowicz PS, Low J, Marshall J et al. Phase I trial of a novel matrix metalloproteinase inhibitor batimastat (BB-94) in patients with advanced cancer. Invest New Drug 1996;14:193-202.
50. Wojtowicz PS, Torri J, Johnson M et al. Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. J Clin Oncol 1998;16:2150-2156.